University of the Pacific

Scholarly Commons
All Dugoni School of Dentistry Faculty Articles

All Faculty Scholarship

10-12-2017

The P2X7 receptor mediates Toxoplasma gondii Control in
Macrophages through canonical NLRP3 inflammasome activation
and reactive oxygen species production
Aline Cristina Abreu Moreira-Souza
Universidade Federal do Rio de Janeiro

Cassio Luiz Coutinho Almeida-Da-Silva
Universidade Federal do Rio de Janeiro, csilva2@pacific.edu

Thuany Prado Rangel
Universidade Federal do Rio de Janeiro

Gabrielle da Costa Rocha
Universidade Federal do Rio de Janeiro

Maria Bellio
Universidade Federal do Rio de Janeiro

See
next
page
additional
authors
Follow
this
andfor
additional
works
at: https://scholarlycommons.pacific.edu/dugoni-facarticles
Part of the Dentistry Commons

Recommended Citation
Moreira-Souza, A. C., Almeida-Da-Silva, C. L., Rangel, T. P., da Costa Rocha, G., Bellio, M., Zamboni, D. S.,
Vommaro, R. C., & Coutinho-Silva, R. (2017). The P2X7 receptor mediates Toxoplasma gondii Control in
Macrophages through canonical NLRP3 inflammasome activation and reactive oxygen species
production. Frontiers in Immunology, 8(OCT), DOI: 10.3389/fimmu.2017.01257
https://scholarlycommons.pacific.edu/dugoni-facarticles/706

This Article is brought to you for free and open access by the All Faculty Scholarship at Scholarly Commons. It has
been accepted for inclusion in All Dugoni School of Dentistry Faculty Articles by an authorized administrator of
Scholarly Commons. For more information, please contact mgibney@pacific.edu.

Authors
Aline Cristina Abreu Moreira-Souza, Cassio Luiz Coutinho Almeida-Da-Silva, Thuany Prado Rangel,
Gabrielle da Costa Rocha, Maria Bellio, Dario Simões Zamboni, Rossiane Claudia Vommaro, and Robson
Coutinho-Silva

This article is available at Scholarly Commons: https://scholarlycommons.pacific.edu/dugoni-facarticles/706

Original Research
published: 12 October 2017
doi: 10.3389/fimmu.2017.01257

The P2X7 Receptor Mediates
Toxoplasma gondii Control in
Macrophages through Canonical
NLRP3 Inflammasome Activation and
Reactive Oxygen Species Production
Aline Cristina Abreu Moreira-Souza1,2†, Cássio Luiz Coutinho Almeida-da-Silva1†,
Thuany Prado Rangel1,2, Gabrielle da Costa Rocha1, Maria Bellio3, Dario Simões Zamboni 4,
Rossiane Claudia Vommaro2 and Robson Coutinho-Silva1*
Immunobiology Program, Biophysics Institute Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro,
Brazil, 2 Parasitology and Cell Biology Program, Biophysics Institute Carlos Chagas Filho, Federal University of Rio de
Janeiro, Rio de Janeiro, Brazil, 3 Department of Immunology, Institute of Microbiology Paulo de Goes, Federal University of
Rio de Janeiro, Rio de Janeiro, Brazil, 4 Department of Cell Biology, Ribeirão Preto Medical School, University of São Paulo,
São Paulo, Brazil
1

Edited by:
Ian Marriott,
University of North Carolina at
Charlotte, United States
Reviewed by:
Carlos De Torre,
IMIB-Arrixaca, Spain
Debora Decote-Ricardo,
Universidade Federal Rural
do Rio de Janeiro, Brazil
*Correspondence:
Robson Coutinho-Silva
rcsilva@biof.ufrj.br
†

These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Microbial Immunology,
a section of the journal
Frontiers in Immunology

Received: 17 July 2017
Accepted: 21 September 2017
Published: 12 October 2017
Citation:
Moreira-Souza ACA, Almeida-daSilva CLC, Rangel TP, Rocha GdC,
Bellio M, Zamboni DS, Vommaro RC
and Coutinho-Silva R (2017) The
P2X7 Receptor Mediates Toxoplasma
gondii Control in Macrophages
through Canonical NLRP3
Inflammasome Activation and
Reactive Oxygen Species Production.
Front. Immunol. 8:1257.
doi: 10.3389/fimmu.2017.01257

Toxoplasma gondii (T. gondii) is the protozoan parasite that causes toxoplasmosis, a potentially fatal disease to immunocompromised patients, and which affects approximately 30%
of the world’s population. Previously, we showed that purinergic signaling via the P2X7
receptor contributes to T. gondii elimination in macrophages, through reactive oxygen species (ROS) production and lysosome fusion with the parasitophorous vacuole. Moreover,
we demonstrated that P2X7 receptor activation promotes the production of anti-parasitic
pro-inflammatory cytokines during early T. gondii infection in vivo. However, the cascade
of signaling events that leads to parasite elimination via P2X7 receptor activation remained
to be elucidated. Here, we investigated the cellular pathways involved in T. gondii elimination triggered by P2X7 receptor signaling, during early infection in macrophages. We
focused on the potential role of the inflammasome, a protein complex that can be coactivated by the P2X7 receptor, and which is involved in the host immune defense against
T. gondii infection. Using peritoneal and bone marrow-derived macrophages from
knockout mice deficient for inflammasome components (NLRP3−/−, Caspase-1/11−/−,
Caspase-11−/−), we show that the control of T. gondii infection via P2X7 receptor activation by extracellular ATP (eATP) depends on the canonical inflammasome effector
caspase-1, but not on caspase-11 (a non-canonical inflammasome effector). Parasite
elimination via P2X7 receptor and inflammasome activation was also dependent
on ROS generation and pannexin-1 channel. Treatment with eATP increased IL-1β
secretion from infected macrophages, and this effect was dependent on the canonical
NLRP3 inflammasome. Finally, treatment with recombinant IL-1β promoted parasite
elimination via mitochondrial ROS generation (as assessed using Mito-TEMPO).
Together, our results support a model where P2X7 receptor activation by eATP inhibits
T. gondii growth in macrophages by triggering NADPH-oxidase-dependent ROS production, and also by activating a canonical NLRP3 inflammasome, which increases IL-1β
production (via caspase-1 activity), leading to mitochondrial ROS generation.
Keywords: P2X7 receptor, Toxoplasma gondii, NLRP3 inflammasome, caspase-1, caspase-11, IL-1β, reactive
oxygen species
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INTRODUCTION

inflammasomes (16, 17). Activation of the canonical NLRP3
inflammasome is trigged by cytosolic stress conditions such
as K+ efflux, leakage of lysosome components, mitochondrial
damage, and ROS production (14, 18). Interestingly, the P2X7
nucleotide receptor activation involved in the elimination of
different intracellular parasites, such as Leishmania amazonensis
(19), Porphyromonas gingivalis (20), Mycobacterium tuberculosis (21–24), and T. gondii (25–27), induces most of these
stress conditions and, thus, is capable of activating the NLRP3
inflammasome (28–30). Polymorphisms in the human P2X7
receptor are directly associated with host susceptibility to congenital or acquired toxoplasmosis, in immunocompetent patients
(25, 31). Also, P2X7 absence or disruption of P2X7 receptor function increases toxoplasmosis severity in murine infection with
virulent (RH, type I) or non-virulent (Me-49, type II) strains of
T. gondii (27, 32).
Our group demonstrated that P2X7 receptor activation by
extracellular ATP (eATP) in T. gondii-infected macrophages
contributes to parasite elimination by ROS production and
lysosome fusion with the parasitophorous vacuole (26). We also
showed that the P2X7 receptor is an important activator of the
anti-parasitic pro-inflammatory response that occurs in early
T. gondii infection in vivo (32). However, the cascade of intracellular events trigged by purinergic signaling—which results in
parasite control in early infection—remains to be elucidated.
In this work, we used macrophages from knockout mice lacking inflammasome components to examine the hypothesis that
the inflammasome is involved in T. gondii infection control via
eATP and the P2X7 receptor. We also studied the roles of ROS
production and IL-1β secretion induced by P2X7 receptor in
infected cell. Our combined data provide an overall model of the
cellular pathways involved in T. gondii infection control mediated
by the P2X7 receptor, in murine macrophages.

Toxoplasma gondii is a parasitic protozoan from the phylum
Apicomplexa and the etiologic agent of toxoplasmosis, an
important disease that affects 30% of the world’s population
(1, 2). Toxoplasmosis can be transmitted by organ transplantation,
blood transfusion or congenital infection, due to the parasite’s
ability to cross biological barriers (3, 4). In most cases, T. gondii
causes asymptomatic disease, but toxoplasmosis can be fatal in
immunocompromised patients, such as those with HIV/AIDS,
cancer, and organ transplants (2). Also, severe ocular disease
and multiple organ failure in immunocompetent individuals
have been observed in endemic countries, due to the circulation
of atypical parasite strains (5, 6). The current therapy for toxoplasmosis is based on drug combinations such as sulfadiazine/
pyrimethamine, which reduce parasite replication, controlling
host damage and symptoms; however, combination therapy
causes important side effects and does not eliminate the resistant
T. gondii cysts (7, 8).
T. gondii is an obligate intracellular parasite, able to infect
virtually all nucleated cell types in a wide variety of hosts (2).
It has been proposed that T. gondii utilizes innate immune cells,
like macrophages and dendritic cells, to migrate to preferential
infection sites, such as the immune “shielded” environment of the
central nervous system, establishing lifelong chronic infection (9,
10). The parasite survives inside host cells by overcoming many
host antimicrobial mechanisms, including reactive oxygen species (ROS) and nitric oxide (NO) production, lysosome fusion (to
the parasitophorous vacuole), host cell death induction, and the
secretion of pro-inflammatory cytokines and chemokines (11).
Concomitantly, T. gondii triggers the activation of host cell antiinflammatory transcription factors, inducing the over expression
of receptors involved in host cell migration to the brain, which
characterizes the chronic phase of toxoplasmosis (12). The ability
to subvert immune system mechanisms and the fast establishment of the latent (chronic) phase of the disease directly jeopardize treatment for toxoplasmosis.
Inflammasomes are multimeric protein complexes that produce active caspase-1 by cleavage of procaspase-1 (13), and whose
activation triggers maturation of IL-1β/IL-18 and pyroptosis, a
type of inflammatory cell death (14). The inflammasome NLRP3
are formed by nucleotide-binding domain and leucine-rich
repeat-containing (NLR) proteins, an apoptosis-associated speclike protein containing a caspase-recruitment domain (ASC)
protein adaptor and an inactive zymogen, procaspase-1 (Casp-1)
(14). In mice, activation of the NLRP3 inflammasome requires
two signals. First, recognition of a pathogen-associated molecular
pattern by cell surface molecules known as pattern recognition
receptors (PRRs) leads to the transcription of pro-inflammatory
cytokines (15). Then, activation of the cytosolic PRRs results in the
oligomerization of inflammasome components and procaspase-1
cleavage into active caspase-1 (13). The active caspase-1 subsequently cleaves the pro-inflammatory IL-1-family cytokines into
their bioactive forms IL-1β/IL-18 and induces pyroptosis (14).
Inflammasomes involved in caspase-1 activation are known as
canonical inflammasomes, while those related to caspase-11 (in
mice) or caspase-4/5 (in humans) are known as non-canonical
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MATERIALS AND METHODS
Reagents

Adenosine-5’-triphosphate (ATP), N-acetyl cysteine (NAC),
penicillin, streptomycin, HEPES, Mito-TEMPO, apocynin, carbeno
xolone, paraformaldehyde, and bovine serum albumin were purchased from Sigma Aldrich (USA). Fetal bovine serum (FBS) was
from Gibco/Life Technologies (USA). Z-YVAD and recombinant
IL-1β were from R&D Systems (USA).

Mice

The following mouse strains were used in this work: Swiss CF1,
C57BL/6 (wild-type strain), P2X7−/− (originally from the Jackson
Laboratory), Caspase-11−/−, Caspase1/11−/− (Genentech, USA),
and NLRP3−/− mice generated on the C57BL/6 background
(8–12 weeks old) were obtained from the Isogenic Breeding
Unit at Ribeirão Preto Medical School, University of São Paulo,
Ribeirão Preto, Brazil. Mice were maintained at the Animal House
for Transgenic Mice of the Federal University of Rio de Janeiro
(UFRJ), at 22°C in a 12-h light/dark cycle. Mice aged between 8
and 12 weeks were used in all experiments. The procedures for
the care and use of animals were according to the guidelines of
the Brazilian College of Animal Experimentation (COBEA). All
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efforts were made to minimize animal suffering and to reduce
the number of animals used in this study. This study was
approved and followed all the guidelines established by the Ethics
Committee on the Use of Animals (CEUA) of the Biophysic
Institute Carlos Chagas Filho (IBCCF, UFRJ, no. 082/15).

some experiments, cells were pretreated for 40 min with 10 mM
NAC, 2 µM Z-YVAD, 1 µM Apocynin, 50 µM carbenoxolone, or
10 nM Mito-TEMPO, before ATP or IL-1β treatment. Then, cells
were maintained at 37°C (and 5% CO2). After 18 h post-infection,
aliquots of culture supernatants were collected and kept at −20°C,
for IL-1β quantification (see “ELISA”) and cultures were processed
for light microscopy, as described below.

Parasites

T. gondii tachyzoites from the RH strain were maintained in Swiss
CF-1 mice as previously described in Ref. (33). Briefly, 5-week-old
mice were infected intraperitoneally with 106 tachyzoites. After
72 h of infection, parasites were harvested from the peritoneal
cavity by PBS washing and then collected by centrifugation at
1,000 × g for 10 min. Harvested parasites were counted in a
hemocytometer for experimental infections or for the next passage in mice.

Light Microscopy

Infected cells were fixed in 4% paraformaldehyde and stained
with Panoptic (“Panotico Rapido kit,” LaborClin, Brazil) following the manufacturer’s instructions. A minimum of 300 cells/
sample were evaluated by light microscopy, in a Zeiss microscope
(manufacturer). As previously described (33), the percentage
of infection and infection index, which represents the overall
infection load, were determined using the formula:

Bone Marrow-Derived Macrophages
(BMDMs) and Peritoneal Macrophages

iC × 100
TotalC
{% of infection × IntP}
Infection Index =
÷ 100
TotalC
% of infection =

Bone marrow-derived macrophages were generated using L929
cell conditioned media (LCCM) as a source of macrophage colony-stimulating factor, as previously described (34, 35). RPMI
containing 100 U/mL penicillin, 100 µg/mL streptomycin, and
1 mM sodium pyruvate was used throughout the procedure. In
brief, fresh bone marrow from C57BL/6, NLRP3−/−, P2X7−/−,
Caspase-11−/−, and Caspase-1/11−/− mice were obtained and
5 × 106 cells were plated in the petri dishes in RPMI with 20%
FBS and 30% LCCM. On day 3 after plating, fresh medium
was added to the cultures. On day 7 after plating, cells were
harvested, washed with PBS, counted and plated in RPMI
with 10% FBS and 5% LCCM, for cytokine detection assays (in
6-well plates, at 2 × 106 cells/well) or light microscopy analysis
(in 24-well plates with 13 mm coverslips, at 2 × 105 cells/well).
Cells were then incubated at 37°C for at least 18 h before the
start of experiments. All experimental infections and treatments
were performed in RPMI with 10% FBS (but without LCCM).
Macrophage differentiation to >95% purity was confirmed by
flow cytometry as described previously (35), before the start of
each experiment.
Peritoneal macrophages were collected as previously des
cribed (33). Briefly, peritoneal exudates from C57BL/6 mice
were obtained by washing the peritoneal cavity with 10 mL of
sterile PBS. Peritoneal cells were counted by light microscopy,
resuspended in DMEM medium, and 2 × 105 cells were plated
in 24-well plates with 13-mm coverslips for light microscopy
analyzes. Cells were left to adhere for 1 h, at 37°C (and 5% CO2),
and then non-adherent cells were removed by PBS washes before
“supplemented DMEM” (DMEM with 10% FBS, 100 U/ml
penicillin, 100 µg/ml streptomycin, and 10 mM HEPES) was
added to cultures.

where iC is number of infected cells; totalC is the total number of
cells; and IntP is the number of intracellular parasites.

Cytokine Assay—ELISA

IL-1β levels were quantified in supernatant samples from infected
BMDM cultures (see Infection Assays), using the Mouse IL-1
beta/IL-1F2 DuoSet ELISA #DY401 kit, according to the manufacturer’s instructions (R&D Systems).

ROS Assay

To estimate ROS production, cells were plated (at a density of
2 × 105 cells/well) in opaque-black 96-well plates with a transparent and flat bottom. After 2 h of infection with T. gondii, cells were
kept untreated or were subjected to one or both of the following
treatments, in the presence of 2 µM of H2DCFDA: 10 mM NAC
for 30 min, followed by 3 mM ATP for up to 60 min. Fluorescence
was measured at 40, 50, and 60 min of exposure to ATP, using a
Spectra Max3 spectrophotometer (Molecular Devices), at 37°C,
at excitation and emission wavelengths of 490 and 520 nm,
respectively.

Statistical Analyses

A two-tailed t-test was used for comparisons of two groups,
while multiple comparisons were performed by one-way
ANOVA followed by Tukey’s post-test. All statistical analyses
were performed using Graph Pad Prism 5 (La Jolla, CA, USA).

RESULTS

Infection Assays

P2X7 Receptor Activation Promotes
T. gondii Control in Macrophages, via
Inflammasome Activation, Caspase-1
and ROS Production

Cells were infected in supplemented DMEM medium, at 37°C
(and 5% CO2). BMDMs or peritoneal macrophages were infected
at a ratio of 3:1 tachyzoites to host cells for 2 h at 37°C (and 5%
CO2), and non-internalized parasites were removed by PBS
washes. Where required, cells were then incubated for 30 min
in medium containing 3 mM eATP and/or 1 ng/mL IL-1β. In
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These data suggest that, in macrophages, the control of T. gondii
infection mediated by eATP depends on the assembly of the
NLRP3 inflammasome.
We demonstrated previously that P2X7 receptor activation
reduces T. gondii load in macrophages, while also generating ROS
(26). Given that, in macrophages, P2X7 receptor activation is
associated with activation of the NLRP3 inflammasome (15), we
sought to determine if ROS and caspase-1—the hallmark of the
canonical NLRP3 inflammasome—are required for the reduction
of T. gondii burden in BMDMs, via P2X7 receptor signaling.
To address this issue, we infected BMDMs from C57BL/6
(WT) mice with T. gondii tachyzoites followed by pretreatment with NAC or Z-YVAD (which inhibit ROS and caspase-1
activities, respectively) and then treated infected cells with
eATP. We confirmed our previous observations that eATP
reduced the percentage of infected cells (Figure 2A) and the
infection index (Figure 2B), in wild-type macrophage cultures.
This effect was abolished by treatment with either NAC or

peritoneal macrophages and J774.G8 cells (26). However, the
mechanism of P2X7-induced T. gondii infection control in these
cells remained unclear. On the other hand, eATP is capable of
activating the inflammasome in infected cells (30) and promotes
pathogen elimination in different models of infection (36).
Therefore, we investigated whether T. gondii elimination in
infected cells via eATP treatment was dependent on inflammasome activation.
To address this question, we infected BMDMs from
wild-type C57BL/6 mice, as well as from NLRP3−/− and
Caspase1/11−/− mice with T. gondii, and treated infected cells
with eATP (3 mM), which activates the P2X7 receptor (26).
Light microscopy-based quantification of the percentage of
infected cells and the infection index (which combines the proportion of infected cells and the number of parasites per cell)
showed that treatment with eATP decreased the parasite load in
wild-type macrophages, while the parasite load remained high
in cells from NLRP3−/− and Caspase1/11−/− mice (Figure 1).

Figure 1 | Extracellular ATP (eATP)-induced T. gondii control is dependent on NLRP3 and caspase-1/11 molecules. Bone marrow-derived macrophages from
C57BL/6 (WT), NLRP3−/− or Caspase-1/11−/− mice were infected with T. gondii tachyzoites for 2 h and kept untreated, or were treated with 3 mM eATP for 30 min.
Then, cells were incubated at 37°C for a total of 18 h, and stained with Panoptic, for light microscopy quantification of the percentage of infection (A) and the
infection index (B). Treatment with eATP reduced the percentage of infected cells and the infection index in wild-type (C57BL/6) macrophages, but not in the
knockout cells. Normalized data represent mean ± SEM of three independent experiments performed in triplicates. ***p ≤ 0.001 vs. untreated (by two-tailed t-test).

Figure 2 | The decrease in T. gondii infection upon extracellular ATP (eATP) treatment depends on reactive oxygen species (ROS) generation and caspase-1
activation. Wild-type (C57BL/6) bone marrow-derived macrophages were infected with T. gondii tachyzoites for 2 h and then left untreated, or subjected to one of
the following treatments: 10 mM N-acetyl cysteine (NAC) or 2 µM Z-YVAD for 30 min followed by 3 mM eATP, for 30 min. After treatments, cells were incubated for
a further 18 h at 37°C, and stained with Panoptic, for light microscopy quantification of the percentage of infection (A) and the infection index (B). Treatment with
NAD or Z-YVAD before exposure to eATP prevented the eATP-dependent reduction in T. gondii infection. Data represent mean ± SEM of three independent
experiments performed in triplicates. **p ≤ 0.01 and ***p ≤ 0.001 vs. untreated (by one-way ANOVA followed by Tukey’s test).
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Z-YVAD (Figure 2). Thus, the reduction in T. gondii infection
load via eATP and the P2X7 receptor depends on activation of
the canonical NLRP3 inflammasome, and also on ROS production and caspase-1.

contributions, we quantified the parasite load after eATP treatment in BMDMs from C57BL/6 (wild-type), Caspase11−/−, and
Caspase1/11−/− mice. Treatment with eATP reduced the parasite
load in wild-type and Caspase-11−/− macrophages, while no
reduction in parasite load was observed after nucleotide treatment in Caspase1/11−/−cells (Figure 3). Thus caspase-1, but not
caspase-11, is required for eATP-mediated T. gondii infection
control. Combined with the data shown in Figures 1 and 2,
these results confirm that the activation of the canonical NLRP3
inflammasome is crucial for the control of T. gondii infection in
macrophages via P2X7 receptor activation by eATP. These data
also show that caspase-11 is dispensable for pathogen elimination via eATP, while caspase-1 is required for this effect, defining
a role for the canonical inflammasome only (and not for the

A Canonical, but Not a Non-Canonical,
Inflammasome Mediates T. gondii
Elimination via P2X7 Receptor Signaling

Given that P2X7 receptor activation reduces T. gondii infection load in a caspase1/11-dependent manner (Figures 1 and
2), we investigated whether canonical and/or non-canonical
inflammasome were involved in parasite elimination. To differentiate between canonical and non-canonical inflammasome

Figure 3 | P2X7 receptor activation triggers T. gondii elimination via a canonical (but not via a non-canonical) inflammasome. Bone marrow-derived macrophages
(BMDMs) from C57BL/6 (wild-type), and from Caspase-11−/− and Caspase1/11−/−knockout mice (lacking non-canonical and canonical inflammasome effectors,
respectively) were infected with T. gondii tachyzoites for 2 h and then kept untreated, or were treated 3 mM extracellular ATP for 30 min. Then, cells were incubated
at 37°C for a total of 18 h, and stained with Panoptic, for light microscopy observation [(A); representative images of three independent experiments] and for the
quantification of the % of infection (B) and the infection index (C). We observed reduced parasite load in wild-type and Caspase-11−/− BMDMs, but not in
Caspase-1/11−/− cells. Black arrows indicate parasitophorous vacuoles containing T. gondii tachyzoites. Micrographs are representative of three independent
experiments. Data represent mean ± SEM of three independent experiments performed in triplicates. ***p ≤ 0.001 vs. untreated (by two-tailed t-test).
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non-canonical inflammasome) in T. gondii infection control
mediated by purinergic signaling.

inflammasome activation (14). Therefore, we investigated whether
activation of the canonical inflammasome via eATP/P2X7 receptor resulted in the secretion of IL-1β by T. gondii-infected cells.
T. gondii infection itself induced discrete (and similar)
amounts of IL-1β release by WT (C57BL/6), NLRP3−/−and
Caspase1/11−/− BMDMs (Figure 4A). When infected cells
were treated with eATP, IL-1β secretion was potentiated in
WT macrophages but did not increase in cells from NLRP3−/−
or Caspase1/11−/− mice, showing that activation of the

eATP Induces NLRP3 InflammasomeDependent IL-1β Secretion and ROS
Generation in Infected Macrophages

IL-1β is an important pro-inflammatory cytokine in response
to different pathogens (37), and its secretion is induced by

Figure 4 | Extracellular ATP (eATP) is important for IL-1β secretion via canonical NLRP3 inflammasome induction and reactive oxygen species (ROS) production, in
T. gondii-infected macrophages. Bone marrow-derived macrophages from C57BL/6 (WT), NLRP3−/− or Caspase-1/11−/− mice, either uninfected or infected with T.
gondii tachyzoites, were kept untreated or were treated with ATP, and then culture supernatant samples were used to estimate IL-1β secretion (A). Treatment with
3 mM eATP (for 30 min) was performed 2 h post-infection, and all cells were incubated for 24 h prior to IL-1β quantification. Data represent mean ± SEM from
triplicates. For ROS detection, before eATP treatment, some cultures were incubated with 10 mM N-acetyl cysteine (NAC) and ROS production was detected. (B,C)
ROS levels in cells treated for 30 min, with NAC and then with 3 mM eATP (for up to 60 min), 2 h post-infection. ROS levels were estimated by H2DCFDA
fluorescence, at different time-points during treatment with eATP (B), with normalized data from the 50-min time-point in (C). Data represent mean ± SEM of three
independent experiments performed in triplicates. #p ≤ 0.05 and ##p ≤ 0.01 vs. corresponding samples treated with eATP only; ***p ≤ 0.001 vs. the corresponding
untreated control (by one-way ANOVA followed by Tukey’s test).
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canonical NLRP3 inflammasome by eATP (via the P2X7 receptor)
triggers IL-1β secretion in T. gondii-infected macrophages.
ROS production is one of the most potent microbicidal mechanisms against intracellular pathogens, and
T. gondii efficiently block ROS production in order to survive
and evade host immune mechanisms (38). In a previous study,
we showed that treatment with eATP induces ROS production in
murine macrophages (26). To test if T. gondii infection subverts
eATP-induced ROS generation, we quantified ROS levels in
T. gondii-infected peritoneal macrophages at different time-points
(40, 50, and 60 min), after eATP. Exposure to eATP increased
ROS levels, from 40 to 60 min of treatment (Figure 4B), even in
T. gondii-infected cells (Figure 4B). The ROS level increase triggered by eATP after 40 min of treatment was reduced significantly
by exposure to the ROS production inhibitor NAC (Figure 4C).
Together, these results show that eATP induced the production
of key molecules for the control of intracellular parasite infection—ROS and IL-1β—even in the presence of T. gondii and its
evasion mechanisms.

of the parasite load. These data confirm that eATP-induced IL-1β
secretion from macrophages is crucial to T. gondii elimination.

T. gondii Elimination via eATP and IL-1β
Depends on Distinct ROS Generation
Sources

The precise role and origin of the ROS pool that acts as an antiparasitic effector during P2X7 receptor activation remain poorly
defined. Considering that our data support the notion that P2X7
receptor activation induces ROS generation via eATP treatment,
we decided to examine which source of ROS pool is required
for T. gondii infection control triggered by eATP, and whether
this phenomenon is mediated by the canonical inflammasome
effector IL-1β. To examine this question, we pretreated infected
peritoneal macrophages with Mito-TEMPO, an inhibitor of
mitochondrial ROS production, and then treated infected cells
with eATP or recombinant IL-1β. Treatment with Mito-TEMPO
effectively inhibited the control of T. gondii infection by IL-1β,
while eATP treatment still reduced the parasite load even in the
presence of Mito-TEMPO (Figures 6A,B). Then, we pretreated
infected peritoneal macrophages with apocynin, an inhibitor of
NADPH oxidase ROS production, and treated infected cells with
eATP. Treatment with Apocynin completely blocked the eATPinduced reduction of parasite load (Figures 6C,D). Therefore,
while both eATP and IL-1β reduce T. gondii infection load
via ROS generation (Figure 5), the mitochondrial ROS pool
is important only for the effector activity of IL-1β on T. gondii
infection control. IL-1β-independent pathways of T. gondii elimination triggered by eATP are likely to depend on ROS production
via NADPH oxidase.

T. gondii Infection Control via eATP
and IL-1β Depends on ROS Production
and Pannexin-1

Thus far, we showed that eATP treatment inhibits T. gondii
infection in macrophages by a mechanism dependent on the
canonical NLRP3 inflammasome and on ROS production,
and that NLRP3 inflammasome activation in cells treated with
eATP leads to the secretion of IL-1β. To examine in more detail
the relationships between P2X7 receptor activation (by eATP),
IL-1β production and ROS generation, during T. gondii infection control by macrophages, we treated infected peritoneal
macrophages with eATP or recombinant IL-1β, alone or in
combination with the antioxidant NAC. As expected, treatment
with eATP or recombinant IL-1β reduced T. gondii infection in
wild-type macrophages (Figure 5A). Interestingly, the antioxidant NAC completely inhibited the control of T. gondii infection
by eATP and IL-1β in peritoneal macrophages (Figures 5B,C).
These results show that ROS production induced downstream
of P2X7 receptor activation or IL-1β secretion is essential
for the control of T. gondii infection mediated by purinergic
signaling.
Importantly, treatment with recombinant IL-1β reduced
T. gondii infection load even in macrophages lacking the P2X7
receptor (from P2X7−/−mice) (Figures 5D,E). These data indicate that IL-1β is downstream of P2X7 receptor activation in the
signaling network that results in T. gondii infection control by
macrophages. In addition, these experiments confirmed that the
effects of eATP treatment described here depends on the P2X7
receptor, since eATP treatment did not reduce the percentage of
infected cells (Figure 5D) or the infection index (Figure 5E) in
P2X7−/− macrophages.
In order to reinforce the role of IL-1β promoting parasite killing, we assessed if the blockade of pannexin-1 channel, which
is required for IL-1β secretion in macrophages (39) can inhibit
eATP-induced killing of T. gondii. As shown in Figures 5F,G, carbenoxolone pretreatment abolished the eATP-induced control
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DISCUSSION
Toxoplasmosis is a major parasitic disease transmitted by food,
with a widespread distribution and a global human infection rate
of ~30% (1). As toxoplasmosis is an inflammatory disease, the
killing of T. gondii requires both innate and adaptive immune
responses (40). Several lines of evidence—from gene polymorphism data to mouse knockout analysis—support the notion
that P2X7 receptor activity contributes to control toxoplasmosis
infection in vivo, by triggering antimicrobial activities in the
intracellular environment (such as ROS production and lysosome
fusion to the parasitophorous vacuole), and by stimulating proinflammatory events, such as the production of IL-12, IL-1β, and
IFN-γ (27, 32). However, the downstream pathways that lead to
parasite elimination via P2X7 receptor activation had not been
dissected previously. Here, we described the cellular pathways
that contribute to T. gondii killing induced by P2X7 receptor activation, showing that the control of T. gondii infection triggered by
purinergic signaling requires the activity of a canonical NLRP3
inflammasome, and involves the inflammasome-dependent
production of ROS and IL-1β (Figure 7).
IL-1β secretion, ROS production, and cell death are the most
common cellular events linked to P2X7 receptor activation,
and also seem to depend on inflammasome activation (20, 29,
35). ATP, a P2X7 receptor ligand, acts as a second signal to
activate the NLRP3 inflammasome (41). Both NLRP1 and NLRP3
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Figure 5 | The control of T. gondii infection induced by extracellular ATP (eATP) and IL-1β requires the generation of reactive oxygen species and pannexin-1.
Peritoneal macrophages from C57BL/6 (WT) and P2X7−/− mice were infected with T. gondii tachyzoites for 2 h, and then left untreated or subjected to one or both of
the following treatments as indicated: 10 mM N-acetyl cysteine (NAC) or 50 µM carbenoxolone for 40 min, followed by 3 mM eATP or 1 ng/mL IL-1β for 30 min.
Then, cells were incubated at 37°C for a further 18 h, and stained with Panoptic for light microscopy analysis (A) representative images of three independent
experiments, which was used to quantify the percentage of infection (B,D,F) and the infection index (C,E,G) in C57BL/6 (B,C,F,G) and P2X7−/− (D,E) cells. In
(A), black arrows indicate parasitophorous vacuoles containing T. gondii tachyzoites in C57BL/6. Normalized data represent mean ± SEM of three independent
experiments [in (B–E)] and 2 independent experiments [in (F,G)] performed in triplicates. (F,G) are representative experiments. Treatment with eATP or IL-1β reduced
the parasite load in C57BL/6 cells, and this effect was abolished by NAC pretreatment (B,C). Treatment with eATP had no effect in the parasite load in P2X7−/− cells
(D,E) or C57BL/6 cells pretreated with carbenoxolone (F,G). #p ≤ 0.05 and ##p ≤ 0.01 vs. sample treated with ATP only; *p ≤ 0.05 and ***p ≤ 0.001 vs. untreated
(by one-way ANOVA followed by Tukey’s test).
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Figure 6 | The control of T. gondii infection induced by extracellular ATP (eATP) and IL-1β depends on different sources of reactive oxygen species generation.
Peritoneal macrophages from C57BL/6 mice were infected with T. gondii tachyzoites for 2 h and left untreated or subjected to one or more of the following
treatments: 100 nM Mito-TEMPO or 1 µM apocynin for 40 min, followed by 3 mM eATP or 1 ng/mL IL-1β for 30 min. Then, cells were incubated at 37°C for a
further 18 h, and the percentage of infected cells (A,C), and number of parasites per host cell (B,D) were estimated by light microscopy examination, after staining
with Panoptic. Normalized data represent mean ± SEM of three independent experiments performed in triplicates in (A,B) and two independent experiments in
(C,D). ##p ≤ 0.01 and ###p ≤ 0.001 vs. sample treated with ATP only; **p ≤ 0.01 and ***p ≤ 0.001 vs. untreated (by one-way ANOVA followed by Tukey’s test).

Figure 7 | Proposed mechanism of T. gondi infection control mediated by extracellular ATP (eATP)/P2X7 receptor and IL-1β, in macrophages. Binding of eATP to the
P2X7 receptor may lead to pathogen elimination via different mechanisms: the fusion of lysosomes to the parasitophorous vacuole (forming a phagolysosome), reactive
oxygen species (ROS) generation and the activation of the canonical NLRP3 inflammasome. NLRP3 inflammasome activation by eATP potentiates IL-1β release
through caspase-1 activity and, in turn, IL-1β in the extracellular compartment binds to its receptor, triggering T. gondii elimination via mitochondrial ROS generation.
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inflammasomes are involved in the immune responses against T.
gondii infection, and mice lacking the inflammasome effectors caspase-1 and caspase-11 have 95% mortality after T. gondii infection
(42). In agreement with these data, we show here that the control of
T. gondii infection by P2X7 activation in macrophages depends
on the NLRP3 inflammasome, and that the inflammasome
effector caspase-1 is essential for T. gondii infection control by
the P2X7 receptor, because lack of inflammasome components
(NLRP3 and caspase-1) or inhibition of caspase-1 activity by
Z-YVAD abolished the reduction in parasite load after treatment
with ATP. In addition, the release of IL-1β in NLRP3 deficient
mice can be explained by activation of NLRP1 inflammasome
in macrophages of those mice (42). By examining separately the
contributions of caspase-1 and caspase-11 to T. gondii infection
control (using mouse knockout cells) we also show that the
reduction in infection load caused by ATP treatment requires
only caspase-1, and not caspase-11, supporting the hypothesis
that a canonical NLRP3 is activated by the P2X7 receptor, to
reduce T. gondii infection in macrophages.
Pyroptosis was shown to occur in response to P2X7 activation in macrophages (43), and this cell death mechanism can
contribute to the clearance of intracellular pathogens (44). We
did not detect significant cell death after 30 min or 18 h of eATP
treatment (data not shown). In addition, our data suggest that, as
have been shown for several pathogenic bacteria (45), the infection with T gondii may block pyroptosis. Thus, it is possible to
conceive that different intracellular pathogens, not only bacteria,
may subvert the immune response by operating in the inhibition
of pyroptosis.
Even before it interacts with host cells, T. gondii secretes
molecules that downregulate PRRs and, consequently, reduce the
production of pro-inflammatory mediators (46). PRR activation
acts as a first signal for inflammasome activation, inducing the
transcription of genes coding for pro-inflammatory molecules.
When PRR activation is followed by a second signal, it culminates in the cleavage and secretion of IL-1β (47). Our data show
that upon eATP treatment and activation of the P2X7 receptor,
T. gondii is not capable of downregulating the inflammasomeinduced IL-1β secretion efficiently, since we observed that eATP
treatment promotes IL-1β secretion in macrophages from WT
mice. In this context, it is already described that P2X7 receptor
activation leads to pannexin-1 pore formation and it is important
for IL-1β release from macrophages (39). Our data show that
inhibiting pannexin-1 channels, eATP-treated macrophages
lack the ability to control T. gondii infection, which suggests that
eATP-induced IL-1β secretion is crucial for the parasite killing.
The results shown here reinforce the notion that IL-1β secretion
potentiates the microbicidal effect of P2X7 activation.
Reactive oxygen species production is another key mechanism
of intracellular pathogen elimination (48). T. gondii posses a
specialized arsenal of antioxidant molecules and can successfully
neutralize oxidative stress in the host (38). However, our result
show that eATP treatment induced ROS production in murine
macrophages even during T. gondii infection. Importantly,
treatment with the inflammasome final product IL-1β reduced
T. gondii infection load in macrophages, and ROS production
was required for T. gondii infection control by eATP and IL-1β,
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because the pan ROS inhibitor NAC prevented the parasite load
reduction caused by ATP and IL-1β. Our data show that, upon
eATP treatment, ROS production is maintained during T. gondii
infection, suggesting that P2X7 receptor activation overcomes
sophisticated antioxidant mechanisms triggered by the pathogen.
In phagocytes, NADPH oxidase activity and mitochondria are
the two most common sources of ROS involved in immune
response events (48), and the mitochondrial-derived ROS also
activates the NLRP3 inflammasome (49). Here, we found that
ROS derived from mitochondria participates in the control of
T. gondii infection downstream of IL-1β signaling only, while
IL-1β-independent signaling triggered by eATP is capable of
controls T. gondii infection even upon inhibition of mitochondrial
ROS production (by Mito-TEMPO). Therefore, we consider that
NADPH oxidase-derived ROS are involved in the control of
T. gondii infection in macrophages, upon P2X7 signaling activation.

CONCLUSION
Our data demonstrate that eATP treatment reduces T. gondii
infection load in macrophages through activation of the NLRP3
inflammasome, and that eATP promotes IL-1β secretion, and
leads to ROS production, in infected cells. By using knockout
mice for different inflammasome molecules, such as NLRP3 and
caspase1 and 11, we also identified that a canonical (but not a
non-canonical) inflammasome is involved in the eATP-induced
IL-1β secretion and elimination of the intracellular parasites, in
macrophages.
We conclude that P2X7 receptor activation inhibits T. gondii
growth via ROS generated, most likely, from NADPH oxidase
(rather than mitochondrial ROS), while also activating the
canonical NLRP3 inflammasome, which leads to IL-1β secretion
and infection control via mitochondrial ROS production.
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